The Defense Health Agency awarded a $562,500 project grant to Captis Diagnostics Inc., a self-certified small disadvantaged business, to develop an extracellular vesicle-based liquid biopsy assay for predicting pathological complete response in breast cancer patients. The grant project runs from April 1, 2024 to March 31, 2027 and is funded through the Military Medical Research and Development program (CFDA 12.420). This program supports a range of biomedical research to improve health outcomes for military service members, veterans, and their families. Captis Diagnostics has a portfolio of federal contract and grant awards, demonstrating its expertise in advancing innovative diagnostic technologies for cancer and neurological disorders through minimally invasive liquid biopsies and extracellular vesicle isolation methods.